Funded Tech Companies
Dualyx
Headquartered in Zwijnaarde, Dualyx has funding from V-Bio Ventures, Forbion Capital Partners and BGV.
Company Overview
Company Name
Dualyx
Company Status
Private & Independent
Industry
Funding Rounds
Total Funding
Contact Information
Mailing Address
Technologiepark 94
Zwijnaarde, 9052
BE
Zwijnaarde, 9052
BE
Phone
Undisclosed
Website
Email Address
Company Background Information
Overview
Dualyx is a Ghent-based biotech company dedicated to the development of novel Treg based therapies to address the needs of patients with difficult-to-treat autoimmune diseases. The company was founded in 2020 by Luc van Rompaey in a collaborative model with Wurzburg University, Argenx, VIB, Ghent University and KU Leuven. Dualyx has developed a pipeline of highly promising immune modulating programs including DT-001, an antibody agonist program targeting the TNF receptor 2 (TNFR2) which is currently in IND-enabling studies. TNFR2 is widely regarded as a master control switch in for immunosuppression, making it highly attractive for Treg therapies. Dualyx also has a pipeline of additional Treg programs in early development. Dualyx is backed by a group of well-respected investors including: Fountain Healthcare Partners, Forbion, Andera Partners, V-Bio Ventures, BGV, PMV, VIB, HTGF and GFF. ?
Profile
Social Media
Company News
Facebook
YouTube
Last Transaction
5/15/2023
Financing History
Date
Type
Amount
Management Team
Title
Name
Email & Social
Chief Executive Officer
Wouter Verhoeven
Chief Scientific Officer
Luc Rompaey
Company Investors
- V-Bio Ventures
- Forbion Capital Partners
- BGV
- PMV
- Andera Partners
- Fountain Healthcare Partners
- High-Tech Gründerfonds
- GFF
- VIB
Browse more funded tech companies:
Share this article
About Our Venture Capital Database
This venture capital transaction data comes via a partnership with VentureDeal.com, a leading provider of venture capital transaction data.
Additional Resources for Entrepreneurs